Eli Lilly and Co. (NYSE:LLY) discontinued development of enzastaurin (LY31765) after top-line data showed daily enzastaurin missed the primary endpoint of improving disease-free survival (DFS) vs. placebo in the Phase III PRELUDE trial to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL). The trial enrolled 758 patients who achieved a complete response or unconfirmed complete response to R-CHOP chemotherapy and were at high risk of relapse. Enzastaurin is a synthetic protein kinase B (PKB; Akt) and protein kinase C (PKC) beta inhibitor. 
Oncothyreon Inc. (NASDAQ:ONTY) disclosed in its 1Q13 earnings late Thursday that once-daily oral PX-866 plus docetaxel missed the primary endpoint of improving progression-free survival (PFS) vs. docetaxel alone in a cohort of patients with non-small cell lung cancer (NSCLC) in the open-label Phase II portion of a Phase I/II trial to treat advanced metastatic solid tumors. Patients were on as second- or third-line chemotherapy. Oncothyreon expects data later this year from a separate cohort of patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after failure of prior therapy. PX-866, an oral phosphoinositide 3-kinase (PI3K) inhibitor.
No comments:
Post a Comment